DermTech partners with two pharmaceutical companies

DermTech, Inc., a player in non-invasive molecular dermatology, has entered into two collaborations with multi-national pharmaceutical companies, the company said Tuesday without revealing their names.

Vice President, Clinical Operations and Research Contracts at DermTech, Jim Rock said that as gene expression technology of DermTech becomes more transparent to the industry, additional biopharmaceutical companies started approaching the company to assist in early-stage clinical development of their technologies.

“These two recent collaborations are further examples of our value add proposition and leadership in molecular dermatology,” said Rock.

“We continue to focus on offering the newest gene expression technology to enhance the understanding of treatment effects and response rates in target populations with new drugs and treatments, providing an invaluable tool in biopharmaceutical drug development,” he added.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.